Jump Financial
KYTX icon

Jump Financial’s Kyverna Therapeutics KYTX Stock Holding History

Jump Financial’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-101,352
Closed -$903K – 2742
2026
Q2 		$903K Buy
101,352
+48,590
+92% +$431K 0.01% 1235
2026
Q1 		$455K Sell
52,762
-27,537
-34% -$229K 0.01% 1298
2025
Q4 		$755K Buy
+80,299
New +$596K 0.01% 1103
2024
Q3 		– Sell
-66,960
Closed -$502K – 2194
2024
Q2 		$502K Buy
+66,960
New +$1.02M 0.01% 1129

Other funds holding KYTX

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Propel Bio Management
Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Jump Financial's KYTX Position: Q3 2026 in Review

Jump Financial sold out of Kyverna Therapeutics (KYTX) in Q3 2026, closing a stake of 101,352 shares — an estimated $903K sold.

Jump Financial first reported a position in KYTX in Q2 2024 and held it in 4 quarters. The position peaked at $903K in Q2 2026. 82 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

  • Jump Financial reported no remaining Kyverna Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jump Financial sold 101,352 Kyverna Therapeutics shares in Q3 2026, an estimated $903K.
  • Jump Financial first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 4 quarters.
  • Jump Financial's Kyverna Therapeutics position peaked at $903K in Q2 2026.
  • 82 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on Jump Financial's 13F filing for Q3 2026, filed 13 Nov 2026.